Table 5 Efficacy of recent clinical trials with liposomal doxorubicin in mono and combination therapy
From: Nanomedicine review: clinical developments in liposomal applications
References | Years | Phase | Disease | LF | n | Dose by cycle | Efficacy | |
|---|---|---|---|---|---|---|---|---|
ORR (%) | m-PFS (months) | |||||||
Banerjee et al. (2018) | 2018 | II | ROC | PLD | 48 | 40Â mg/m2 IV Q4W | 15 | 3.1 |
Lee et al. (2017) | 2017 | II | ROC | PLD | 40 | 50Â mg/m2 | 5 | 5 |
Monk et al. (2017) | 2017 | II | ROC | PLD | 149 | 40Â mg/m2 | 21.5 | 5.2 |
Marth et al. (2017) | 2017 | III | ROC | PLD | 109 | 50Â mg/m2 Q4W | 21 | 7.2 |
Lindemann et al. (2017) | 2017 | III | ROC | PLD | 86 | 40Â mg/m2 | 16.9 | 12.7 |
Herzog et al. (2016) | 2016 | II | ROC | PLD | 15 | 50 mg/m2 IV Q4W | – | – |
Lee et al. (2017) | 2017 | II | ROC | PLD + carboplatin | 12 | 50 mg/m2 + 5 AUC | 33.3 | 13 |
Sehouli et al. (2016) | 2016 | III | ROC | PLD + carboplatin | 5 | 30 mg/m2 + 5 AUC | 75.1 | 11 |
Nagao et al. (2016) | 2016 | I | ROC | PLD + carboplatin + paclitaxel | 7 | 30 mg/m2 + 60 mg/m2 + 6 AUC | 33 | 12 |
Landrum et al. (2016) | 2016 | I | ROC | PLD + carboplatin + veliparib | 10 | 30 mg/m2 + 5 AUC + 50 mg | 50 | – |
Kim et al. (2015) | 2016 | I | ROC | PLD + carboplatin + farletuzumab | 15 | 30 mg/m2 + 5–6 AUC + 2.5 mg/kg | 73.2 | 10.4b |
Runnebaum et al. (2018) | 2018 | II | ROC | PLD + trabectedin | 77 | 30 mg/m2 + 1.1 mg/m2 IV Q3W | 31 | 6.3 |
Monk et al. (2017) | 2017 | II | ROC | PLD + motolimod | 148 | 40 mg/m2 + 30 mg/m2 | 20.9 | 4.8 |
Marth et al. (2017) | 2017 | III | ROC | PLD + trebananib | 114 | 50 mg/m2 Q4W + 15 mg/kg Q1W | 46 | 7.6 |
Shoji et al. (2017) | 2017 | II | ROC | PLD + irinotecan | 31 | 30 mg/m2 | 32.3 | 2 |
Thaker et al. (2017) | 2017 | I | ROC | PLD + GEN | 7 | 50 mg/m2 + 36 mg/m2 | 29 | 4.7 |
Herzog et al. (2016) | 2016 | II | ROC | PLD + vintafolide | 22 | 50 mg/m2 IV Q4W + 7.5 mg IV Q2W | – | – |
Jehn et al. (2016) | 2016 | II | MBC | Caelix® | 25 | 25 mg/m2 | 4.5 | 1.75a |
Harbeck et al. (2016) | 2016 | III | MBC | PLD | 105 | 150 mg/m2 | – | 6a |
Chang et al. (2018) | 2018 | II | MBC | PLD + CPM | 21 | 30 mg/m2 Q4–6W + 60 mg/m2 PO daily | 21 | 6.4 |
Tampaki et al. (2018) | 2018 | II | BC | PLD + CPM + bevacizumab + paclitaxel | 62 | 30 mg/m2 + 600 mg/m2 + 8 mg/kg + 120 mg/m2 Q2W | 95.2 | – |
Basho et al. (2016) | 2016 | I | TNBC | PLD + bevacizumab + temsirolimus | 24 | 30 mg/m2 + 15 mg/kg Q3W + 25 mg Q1W IV | 21 | 4 |
PLD + bevacizumab + everolimus | 9 | 30 mg/m2 + 15 mg/kg Q3W IV + 7.5 mg PO daily | ||||||
Rocca et al. (2017) | 2017 | I | BC | PLD + lapatinib | 9 | 30 mg/m2 Q3W + 1500 mg/day on days 1–21 | 11 | 5.75a |
Coltelli et al. (2017)b | 2017 | II | BC | Myocet® + CPM + paclitaxel | 47 | 60 mg/m2 + 600 mg/m2 IV Q3W + 80 mg/m2 Q1W | – | – |
Orlowski et al. (2016) | 2016 | III | RMM | PLD + bortezomib | 324 | 30 mg/m2 + 1.3 mg/m2 | – | 33.0c |
Cohen et al. (2018) | 2018 | II | MM | PLD + pomalidomide + dexamethasone | 16 | 5 mg/m2 + 40 mg IV days 1, 4, 8 and 11 + 4 mg/day for 21 days, 28-day cycle | 31 | 5 |
Becker et al. (2016) | 2016 | II | MM | PLD + bortezomib + CPM + dexamethasone | 20 | 30 mg/m2 IV Q4W + 1.6 mg/m2 + 300 mg/m2 + 40 mg three times by cycle | 90 | – |
Voorhees et al. (2017) | 2017 | I | RMM | PLD + bortezomib + vorinostat | 32 | 30 mg/m2 + 1.3 mg/m2 + escalating dose of vorinostat | 65 | 13.9 |
Casadei et al. (2018) | 2018 | I | MHL | PLD | 9 | 60 mg IV Q3W | 50 | – |
Luminari et al. (2017) | 2017 | II | DLBCL | Myocet® + CPM + vincristine + prednisone + rituximab | 49 | 50 mg/m2 + 750 mg/m2 and 1.4 mg/m2 day 1 + 100 mg days 1–5 + 375 mg/m2 day 3 of each cycle | 72 | 17 |
Fridrik et al. (2016) | 2016 | II | DLBCL | Myocet® + CPM + vincristine + prednisolone + rituximab | 40 | 50 mg/m2 + 750 mg/m2 + 1.4 mg/m2 + 40 mg/m2/day for 5 days + 375 mg IV QW3 | 97.5 | – |